Discovery Pipeline
In addition to our clinical-stage therapeutic programs, our proprietary phage display technology and expertise allow us to develop a broad pipeline of discovery and preclinical drug candidates focused on unmet medical needs.
Of this pipeline, the most advanced is DX-2240. Our DX-2240 antibody has a novel mechanism of action that targets the Tie-1 receptor on tumor blood vessels. With demonstrated activity against a broad range of solid tumor types in preclinical testing, DX-2240 may have therapeutic potential in multiple cancer indications. This novel antibody candidate was licensed to sanofi-aventis as part of a strategic collaboration that included a license to our patented phage display technology and co-development options for future antibody drug candidates discovered by sanofi aventis. Sanofi-aventis is responsible for the ongoing development of DX-2240.